Statement: the primary trial and the secondary trial reported the same number of dehydrated patients during the studies.
Primary_evidence: Adverse Events 1:   Total: 9/46 (19.57%)   Febrile neutropenia 1/46 (2.17%)   Cardiac disorder 1/46 (2.17%)   Diarrhea 1/46 (2.17%)   Upper gastrointestinal hemorrhage 1/46 (2.17%)   Chest pain 1/46 (2.17%)   Fatigue 1/46 (2.17%)   Neutrophil count decreased 2/46 (4.35%)   Platelet count decreased 1/46 (2.17%)   Anorexia 1/46 (2.17%)   Dehydration 1/46 (2.17%)   Serum potassium increased 1/46 (2.17%)
Secondary_evidence: Adverse Events 1:   Total: 13/50 (26.00%)   Febrile neutropenia 3/50 (6.00%)   Neutropenia 1/50 (2.00%)   Pancreatitis 1/50 (2.00%)   Cholangitis 1/50 (2.00%)   Cholelithiasis 1/50 (2.00%)   Anaphylactic reaction  [1]1/50 (2.00%)   Pneumonia 1/50 (2.00%)   Pneumonitis chemical 1/50 (2.00%)   Spinal compression fracture 1/50 (2.00%)   Dehydration 1/50 (2.00%)   Electrolyte imbalance 1/50 (2.00%)